Kamada Ltd
A maker of plasma-derived and recombinant protein therapies, Kamada Ltd produces medicines for people with rare conditions. Its flagship product, GLASSIA, treats alpha-1 antitrypsin deficiency, a genetic disorder that can damage the lungs and liver, and the company also makes KamRAB for rabies exposure and KamRho for Rh incompatibility in pregnancy. Founded in Israel in 1990, the company takes its name from the Hebrew word for "longing," and its therapies reach patients in dozens of countries.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Phoenix Financial Ltd. | 13G/APassive | 4.6% | 2.65M | Aug 20, 2026 |
| RECANATI LEON | 13G/APassive | 6% | 3.48M | Mar 16, 2026 |
| Gov Financial Holdings Ltd. | 13G/APassive | 2.5% | 1.46M | Mar 16, 2026 |
| Insight Capital Ltd. | 13G/APassive | 2.3% | 1.35M | Mar 16, 2026 |
| Leon Recanati | 13G/APassive | 6.07% | 3.49M | Mar 5, 2025 |
| Gov Financial Holdings Ltd. | 13G/APassive | 2.53% | 1.46M | Mar 5, 2025 |
| Insight Capital Ltd. | 13G/APassive | 2.34% | 1.35M | Mar 5, 2025 |